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Fucoidan,  a sulfated  polysaccharide  found  in  marine  algae  and  brown  seaweeds,  has  been  shown  to  inhibit
the in vitro  growth  of human  cancer  cells.  This  study  was  conducted  in  cultured  human  bladder  cancer  EJ
cells to  elucidate  the  possible  mechanisms  by which  fucoidan  exerts  its anti-proliferative  activity,  which
until  now  has  remained  poorly  understood.  Fucoidan  treatment  of EJ cells  resulted  in dose-dependent
inhibition  of  cell  growth  and  induced  apoptotic  cell  death.  Flow  cytometric  analysis  revealed  that  fucoidan
led  to  G1  arrest  in cell cycle  progression.  It  was  associated  with  down-regulation  of  cyclin  D1,  cyclin E,
and cyclin-dependent-kinases  (Cdks)  in a concentration-dependent  manner,  without  any  change  in CdkJ cells
1 arrest
poptosis
RB
inhibitors,  such  as  p21  and  p27.  Furthermore,  dephosphorylation  of  retinoblastoma  protein  (pRB)  by  this
compound  was  associated  with  enhanced  binding  of pRB  with  the  transcription  factors  E2F-1  and  E2F-4.
Overall,  our  results  demonstrate  that  fucoidan  possesses  anticancer  activity  potential  against  bladder
cancer  cells by  inhibiting  pRB  phosphorylation.
© 2015  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
Bladder cancer is any of several types of malignancy arising
rom the epithelial lining of the urinary bladder. In the United
tates, bladder cancer is the fourth most common type of cancer
n men  and the ninth most common cancer in women, although
he incidence of bladder cancer in Asia is much lower (Kakehi et al.,
010; Abdollah et al., 2013). Despite recent advances in surgical and
hemotherapeutic procedures, long-term survival rates are poor,
nd the most common cause of mortality is recurrence with metas-
asis (Racioppi et al., 2012). Therefore, it is important to develop
ther effective strategies to improve the survival rate for bladder
ancer patients.Several epidemiological studies have revealed that dietary
ntake of marine algae and seaweeds are protective against the
isk of various types of malignancies (Kim et al., 2011; Park and
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E-mail: choiyh@deu.ac.kr (Y.H. Choi).
1 These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.bjp.2015.03.011
102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier EditoraPezzuto, 2013; Ahmed et al., 2014). Brown seaweeds are used as
an important healthcare food and a pharmaceutical product in
Asian countries. Fucoidan is a major sulfated polysaccharide found
in brown seaweed; it has been well characterized and is known
to have various biological functions, including antioxidant, anti-
inﬂammatory, and anticancer effects (Li et al., 2008; Senni et al.,
2011; Fitton, 2011; Wang et al., 2012; Senthilkumar et al., 2013;
Thomas and Kim, 2014). We  reported recently that fucoidan may
offer substantial therapeutic potential for treatment of inﬂam-
matory and neurodegenerative diseases that are accompanied by
microglial activation (Park et al., 2011a). In addition, fucoidan
suppresses cancer cell proliferation and inhibits the growth of
transplanted tumor xenografts by inducing apoptosis and/or by
blocking abnormal cell cycle progression at the G1 or G2/M phase
(Riou et al., 1996; Fukahori et al., 2008; Park et al., 2011b, 2013;
Zhang et al., 2011, 2013; Hsu et al., 2013; Xue et al., 2013; Yang
et al., 2013; Park et al., 2014; Banafa et al., 2013; Chen et al., 2014;
Senthilkumar and Kim, 2014; Cho et al., 2014). However, this effect
is selective for cancer cells, as normal cell lines are resistant to cell
cycle arrest and apoptosis by fucoidan. Moreover, fucoidan also
inhibits migration and invasion of highly metastatic cancer cells
 Ltda. All rights reserved.
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Table 1
Oligonucleotides used in RT-PCR.
Gene name Sequence
Cyclin D1
Sense 5′-TGG-ATG-CTG-GAG-GTC-TGC-GAG-GAA-3′
Antisense 5′-GGC-TTC-GAT-CTG-CTC-CTG-GCA-GGC-3′
Cyclin E
Sense 5′-AGT-TCT-CGG-CTC-GCT-CCA-GGA-AGA-3′
Antisense 5′-TCT-TGT-GTC-GCC-ATA-TAC-CGG-TCA-3′
Cdk2
Sense 5′-GCT TTC TGC CAT TCT CAT CG-3′
Antisense 5′-GTC CCC AGA GTC CGA AAG AT-3′
Cdk4
Sense 5′-ACG-GGT-GTA-AGT-GCC-ATC-TG-3′
Antisense 5′-TGG-TGT-CGG-TGC-CTA-TGG-GA-3′
Cdk6
Sense 5′-CGA-ATG-CGT-GGC-GGA-GAT-C-3′
Antisense 5′-CCA-CTG-AGG-TTA-GAG-CCA-TC-3′
p21
Sense 5′-CTC AGA GGA GGC GCC ATG-3′
Antisense 5′-GGG CGG ATT AGG GCT  TCC-3′
p27
Sense 5′-AAG-CAC-TGC-CGG-GAT-ATG-GA-3′
Antisense 5′-AAC-CCA-GCC-TGA-TTG-TCT-GAC-3′H.Y. Park et al. / Revista Brasileira
ia down-regulation of matrix metalloproteinases and inhibition of
he phosphoinositide 3-kinase/Akt and nuclear factor-kB signaling
athways (Saitoh et al., 2009; Lee et al., 2012; Wang et al., 2014;
enthilkumar and Kim, 2014). However, the molecular mechanisms
f its anti-proliferative actions on human bladder carcinoma cell
rowth have not yet been examined. Thus, the purpose of this
tudy was to investigate the effects of fucoidan on cell prolifera-
ion of the human bladder carcinoma cell line EJ and to explore the
otential mechanisms of the effects. Our data indicate that fucoidan
nhibited the growth of EJ cells in a concentration-dependent man-
er, arresting them in the G1 phase of their cell cycle and inducing
poptosis.
aterials and methods
ell culture
EJ cells were purchased from American Type Culture Collec-
ion (ATCC, Manassas, VA, USA) and maintained in RPMI-1640
edium (GIBCO-BRL, Gaithersburg, MD)  supplemented with 10%
etal bovine serum (FBS) and 2 mM of l-glutamine and peni-
illin/streptomycin. The cells were cultured in an incubator with
% CO2 at 37 ◦C. Fucoidan was purchased from Sigma-Aldrich (St.
ouis, MO,  USA) and dissolved in phosphate-buffered saline (PBS)
s a stock solution at a 200 mg/ml  concentration, and the stock solu-
ion was then diluted with the medium to the desired concentration
rior to use.
TT  assay
Measurement of cell viability was determined using the 3-(4,5-
imethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
igma-Aldrich) assay, which is based on the conversion of MTT  to
TT-formazan by mitochondria. In brief, cells (2 × 104 cells/well)
ere seeded in 24-well plates and exposed to fucoidan for 48 h.
fter treatment, 5 mg/ml  MTT  solution was added, followed by 3 h
ncubation at 37 ◦C in the dark, and the media was  then removed.
he formazan precipitate was dissolved in dimethyl sulfoxide
Sigma-Aldrich), and absorbance of the formazan product was
easured at a wavelength of 540 nm with an enzyme-linked
mmunosorbent assay (ELISA) reader (Molecular Devices, Sunny-
ale, CA, USA) (Lee et al., 2014). For the morphological study, cells
ere photographed directly using an inverted microscope (Carl
eiss, Oberkochen, Germany).
low cytometry analysis
Exponentially growing cells were compared to cells treated with
arious concentrations of fucoidan for 48 h. After treatment with
ucoidan, the cells were collected and ﬁxed in 70% ethanol at 4 ◦C
or 30 min, and the DNA content of cells was stained with pro-
idium iodide (PI) using a DNA staining kit (CycleTEST PLUS Kit,
ecton Dickinson, San Jose, CA, USA) in accordance with the manu-
acturer’s instructions. The cells were then subjected to a FACScan
ow cytometer (Becton Dickinson) with the percentages of cells in
ifferent phases of the cell cycle calculated from DNA histograms.
ells with sub-G1 DNA content were considered apoptotic cells
Kim et al., 2014).
orphological observation of nuclear change
After culture with various concentrations of fucoidan, cells were
ashed twice with PBS and ﬁxed with 3.7% paraformaldehyde
Sigma-Aldrich) in PBS for 10 min  at room temperature. The ﬁxed
ells were washed twice with PBS and stained with 4,6-diamidino-
-phenylindole (DAPI, Sigma-Aldrich) solution for 10 min  at roomGAPDH
Sense 5′-CGG-AGT-CAA-CGG-ATT-TGG-TCG-TAT-3′
Antisense 5′-AGC-CTT-CTC-CAT-GGT-GGT-GAA-GAC-3′
temperature. The cells were washed two  more times with PBS. Cov-
erslips were mounted on glass slides and analyzed by ﬂuorescence
microscopy using a Zeiss Axiophot microscope (Carl Zeiss).
Annexin-V staining
To analyze apoptosis, the cells were treated with the indicated
concentrations of fucoidan for 48 h and resuspended in an annexin-
V binding buffer containing 10 mM HEPES/NaOH (pH 7.4), 140 mM
NaCl, and 2.5 mM CaCl2. Aliquots of the cells were incubated with
annexin-V ﬂuorescein isothiocyanate (FITC, R&D Systems, Min-
neapolis, MN,  USA), mixed, and incubated for 15 min  at room
temperature in the dark. PI at a concentration of 5 g/ml was  added
to distinguish necrotic cells. The apoptotic cells (Annexin V+/PI−
cells) were measured by a ﬂuorescence-activated cell sorter analy-
sis in a FACScan ﬂow cytometer (Park and Han, 2014).
RNA extraction and reverse transcription-polymerase chain
reaction (PCR)
Total RNA was  isolated using an RNeasy minikit (Qiagen, La Jolla,
CA, USA) and primed with random hexamers to synthesize comple-
mentary DNA using AMV  reverse transcpriptase (Amersham Corp.,
Arlington Heights, IL, USA) following the manufacturer’s instruc-
tions. PCR was performed in a Mastercycler (Eppendorf, Hamburg,
Germany) with the indicated primers, which were purchased from
Bioneer (Seoul, Republic of Korea), in Table 1. The conditions for the
PCR reactions were 1× (94 ◦C for 3 min), 35X (94 ◦C for 45 s; 58 ◦C for
45 s; and 72 ◦C for 1 min), and 1× (72 ◦C for 10 min). The ampliﬁca-
tion products obtained by PCR were electrophoretically separated
on a 1.0% agarose gel and visualized by ethidium bromide (EtBr,
Sigma-Aldrich) staining (Gong et al., 2014). In a parallel experi-
ment, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as an internal control.
Total protein extraction, immunoprecipitation, and Western blot
analysis
For isolation of total protein fractions, the cells were har-
vested and washed once with ice-cold PBS, and lysed with cell
lysis buffer [20 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100,
2.5 mM sodium pyrophosphate, 1 mM EDTA, 0.5 g/ml leupeptin,
1% Na3CO4, 1 mM phenylmethane-sulfonyl ﬂuoride], and pro-
tein concentrations were quantiﬁed using the Bio-Rad protein
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Fig. 1. Inhibition of cell viability and induction of G1 arrest by fucoidan treatment
in  human bladder cancer EJ cells. (A) Cells were treated with the indicated concen-
trations of fucoidan for 48 h. The cells were harvested, and the percentage of cell
viability was calculated with an MTT  assay. Data are presented as mean ± SD in trip-
licate. Signiﬁcance was  determined by the Student’s t-test (*p < 0.05 vs. untreated
control). (B) The cells were collected, ﬁxed, and stained with PI for ﬂow cytometry
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Fig. 2. Induction of apoptosis by fucoidan treatment in EJ cells. The cells were treated
with various concentrations of fucoidan for 48 h. (A) The morphological changes of
the  cells were imaged using an inverted microscope (original magniﬁcation, 200×).
(B)  The cells were ﬁxed and stained with DAPI solution. After 10 min  incubation at
room temperature, the stained nuclei were observed with a ﬂuorescent microscope
(original magniﬁcation, 400×). (C) The cells were harvested for determining the per-nalysis. DNA content is represented on the x-axis, and the number of cells counted
s  represented on the y-axis. Each point represents the mean of two independent
xperiments.
ssay (Bio-Rad Lab., Hercules, CA, USA), following the proce-
ure described by the manufacturer. For immunoprecipitation, cell
xtracts were incubated with immunoprecipitating antibodies in
xtraction buffer for 1 h at 4 ◦C, and then the immunocomplexes
ere precipitated with protein A-Sepharose beads (Sigma-Aldrich).
or Western blot assay, the total proteins and immunoprecipitated
roteins were subjected to electrophoresis on sodium dodecyl
ulphate (SDS)–polyacrylamide gels and transferred to nitrocel-
ulose membranes (Schleicher & Schuell, Keene, NH, USA) by
lectroblotting. Blots were subsequently blocked with 5% non-fat
ilk and probed with the desired antibodies for 1 h at 4 ◦C, incu-
ated with diluted enzyme-linked secondary antibody at room
emperature for a further 1 h, and then visualized by enhanced
hemiluminescence (ECL, Amersham) according to recommended
rocedures. Eextracellular-regulated kinase (ERK) was used as an
nternal control. The primary antibodies were purchased from
anta Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Peroxidase-
abeled donkey antirabbit immunoglobulin and peroxidase-labeled
heep antimouse immunoglobulin were purchased from Amer-
ham.
tatistical analysis
The data were expressed as means ± SD for triplicate experi-
ents. Statistical analyses were performed using a Student’s t-test.
 p value <0.05 was considered statistically signiﬁcant.
esults
ucoidan inhibits cell viability and induces G1 arrest in EJ cells
To determine whether fucoidan inﬂuenced the cell viability of
he EJ cells, the cells were cultured in the presence of fucoidan for
8 h, and the cell viability was determined with an MTT  assay. As
hown in Fig. 1A, fucoidan reduced the viability of the EJ cells in
 concentration-dependent manner. The cell cycle phase distribu-
ion of exponentially growing EJ cells was next compared to cellscentage of annexin-V positive/PI negative (apoptotic cells). The data are expressed as
the mean ± SD of three independent experiments. The signiﬁcance was  determined
by  the Student’s t-test (*p  < 0.05 vs. untreated control).
treated with fucoidan. Compared with the untreated control, the
fucoidan-treated cells accumulated in the G1 phase of the cell cycle
in a concentration-dependent manner (Fig. 1B), and there was a
decrease in the number of cells in the S and G2/M phases. Taken
together, these results suggest that the growth inhibitory effect of
fucoidan on EJ cells is the result of it blocking the G1 phase.
Fucoidan induces apoptosis in EJ cells
As fucoidan induced morphological changes, such as membrane
blebbing and a reduction in cell volume under the same condi-
tions (Fig. 2A), we assessed the effect of fucoidan treatment on
the apoptotic characteristics of the EJ cells to determine whether
apoptosis was involved in fucoidan-mediated antiproliferation[0].
Fig. 2B reveals that nucleic morphological changes of apoptosis as
indicated by representative images of condensed and fragmented
nuclei were clearly evident in fucoidan-treated EJ cells in contrast
to the untreated cells. To quantify fucoidan-induced apoptosis, the
EJ cells treated with fucoidan were stained with annexin V-FITC and
analyzed by ﬂow cytometry. As shown in Fig. 2C, fucoidan increased
the annexin-V-FITC stained apoptotic population of cells, and these
effects were dose dependent. These observations indicate that the
inhibition of cell viability observed in response to fucoidan is also
associated with the induction of apoptosis.
Effect of fucoidan on the expression of cell cycle checkpoint
regulators
To further investigate the molecular mechanisms underlying
fucoidan-induced G1 arrest, the EJ cells were treated with fucoidan,
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Fig. 3. Down-regulation of G1-associated cyclins and Cdks by fucoidan treatment in EJ cells. (A) After treatment with various concentrations of fucoidan for 48 h, the cells
were  collected, and total RNA was isolated and reverse-transcribed. The resulting cDNAs were then subjected to PCR with the indicated primers, and the reaction products
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llustrated in Fig. 3, fucoidan suppressed the expression of biomark-
rs, such as cyclin D1, cyclin E, cyclin-dependent-kinase (Cdk) 2,
dk4, and Cdk6, in the transition of the G1 to the S phase in a
oncentration-dependent manner. However, fucoidan did not sig-
iﬁcantly affect the levels of Cdk inhibitors, such as p21 and p27
Fig. 4).
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eaction products were subjected to electrophoresis in 1.0% agarose gel and visual-
zed by EtBr staining. GAPDH was used as an internal control. (B) After incubation
ith  fucoidan under the same conditions, the cell lysates were separated, and equal
mounts of total cell lysates were subjected to SDS–polyacrylamide gels, transferred,
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resented at the bottom of each of the results as relative values of the GAPDH and
RK expression, respectively.e indicated antibodies. ERK was used as an internal control. The relative ratios of
 the results as relative values of the GAPDH and ERK expression, respectively.
Fucoidan down-regulates pRB phosphorylation and increases the
binding of pRB and E2Fs
As D-type cyclins and cyclin E-stimulated Cdk activity con-
verges in hyperphosphorylation of the retinoblastoma protein
(pRB), the effect of fucoidan on the phosphorylation status of
pRB was  investigated by Western blot analysis. Fucoidan caused a
remarkable decrease in total levels of pRB expression and changed
from a hyperphosphorylated form to a hypophosphorylated form
(Fig. 5A). Furthermore, co-immunoprecipitation analysis indicated
that there appeared to be no association between pRB and E2Fs,
such as E2F-1 and E2F-4, in the untreated control cells[0]. How-
ever, there was  a strong increase in the binding of pRB and E2Fs
in the fucoidan-treated EJ cells (Fig. 5B), suggesting that fucoidan
inhibits the release of E2Fs protein from pRB.
Discussion
Although fucoidan exerts various pharmacological activities,
such as anti-inﬂammatory, antioxidant, and anticancer effects
(Riou et al., 1996; Li et al., 2008; Fukahori et al., 2008; Saitoh et al.,
2009; Fitton, 2011; Senni et al., 2011; Park et al., 2011b, 2013; Zhang
et al., 2011, 2013; Wang et al., 2012; Lee et al., 2012; Liu et al., 2012;
Hsu et al., 2013; Xue et al., 2013; Yang et al., 2013; Senthilkumar
et al., 2013; Park et al., 2014; Banafa et al., 2013; Chen et al., 2014;
Senthilkumar and Kim, 2014; Wang et al., 2014), the anti-cancer
activity of fucoidan in human bladder cancer cells has rarely been
reported. Therefore, we  elucidated the ability of fucoidan to inhibit
the growth of human bladder cancer EJ cells. In this study, we found
that fucoidan shows considerable potential to inhibit the prolifer-
ation of EJ cells via cell cycle arrest in the G1 phase and apoptosis
induction.
Cancer cells exhibit deregulation of cell cycle and apoptosis and
activation of signal transduction, resulting in abnormal prolifera-
tion. Cyclins and Cdks play an important role in the regulation of
the cell cycle through the formation of cyclin/Cdk complexes. Alter-
ation in the formation of these complexes could lead to increased
or decreased cell growth and proliferation followed by differenti-
ation and/or cell death by apoptosis (Sperka et al., 2012; Canavese
et al., 2012). In general, D-type cyclins/Cdk4/6 and cyclin E/Cdk2
complexes are crucial factors in the transition of the G1 to the S
phase cell cycle, and these factors are negatively regulated by Cdk
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the relative ratios of expression in the results of the Western blotting were pre-
ented at the bottom of each of the results as relative values of the ERK expression
r  untreated control, respectively.
nhibitors, including p21 and p27 (Dobashi et al., 2003; Paternot
t al., 2010). In the present study, the results from RT-PCR and
mmunoblotting analysis clearly demonstrated that the levels of
yclin D1 and cyclin E expression were markedly inhibited by
ucoidan treatment at both transcriptional and translational lev-
ls (Fig. 3). In addition, fucoidan-induced G1 arrest was correlated
ith the down-regulation of Cdks, such as Cdk2, Cdk4, and Cdk6.
lthough, a recent study indicated that fucoidan down-regulated
yclin E, Cdk2, Cdk4 resulting in G0/G1 arrest through binding of
dk inhibitor p21 to Cdk2 and Cdk4 in cells treated with fucoidan in
uman bladder cancer 5637 cells (Cho et al., 2014), the expression
f Cdk inhibitors such as p21 and p27 was remained unchanged in
ucoidan-treated EJ cells (Fig. 4).
On the other hand, pRB as a tumor suppressor is also impor-
ant for cell cycle progression during the G1 to S phase transition.
ephosphorylation of pRB inhibits cell cycle progression by inter-
cting with transcription factors of the E2F family, whereas
hosphorylation of pRB results in induction of cell cycle progres-
ion through the breaking of pRB/E2F complexes (Dobashi et al.,
003; Paternot et al., 2010). Therefore, if the levels of either protein
re decreased or the association between their respective bindings
artners is diminished, a concomitant decrease in the degree of pRB
hosphorylation would be expected. In conjunction with down-
egulation of total levels of pRB, the data showed that treatment
ith fucoidan inhibited the phosphorylation of pRB and enhanced
he association of pRB and E2Fs (Fig. 5). The role of Cdk inhibitorsrmacognosia 25 (2015) 246–251
has attracted attention in the induction of G1 phase arrest, which
is related to the restriction of the proliferation of cancer cells via
fucoidan treatment. However, according to Boo et al. (2012), restric-
tion of E2F expression plays an important role in inducing G1 cell
cycle arrest in PC-3 prostatic cancer cells, along with the increased
expression of Cdk inhibitor p21. Moreover, a recent study con-
ducted in our lab revealed that phosphorylation inhibition of pRB
was simultaneously involved in addition to the expression increase
of Cdk inhibitor p21 in T24 bladder cancer cells’ G1 arrest brought
about by fucoidan (Park et al., 2014). Hence, even if cancer cells’ G1
arrest resulting from fucoidan treatment differs according to types
of cancer cells, it can at least be said that expression increase of
Cdk inhibitors such as p21 and phosphorylation inhibition play an
important factors in G1 arrest.
Conclusions
In conclusion, the results presented here demonstrate that:
(i) reduced survival of EJ cells after exposure to fucoidan is
associated with G1 phase cell cycle arrest and apoptosis induc-
tion; (ii) fucoidan inhibits cell cycle progression in the G1 phase
by decreasing G1-related cyclins and Cdks; (iii) treatment with
fucoidan results in increased binding of pRB to E2Fs. These novel
phenomena have not been previously described in bladder cancer
cells and suggest that fucoidan and related compounds may have
signiﬁcant potential in the development of cancer treatments.
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